Scientific Sessions 2024  /  Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations  /  Discussant: OLE & HELIOS-B
Logo

American Heart Association

  116
  0

Final ID:

Discussant: OLE & HELIOS-B

  • Grogan, Martha  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Kittleson, Michelle  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Nair, Ajith  ( Baylor College of Medicine , Houston , Texas , United States )
  • Grodin, Justin  ( UT SOUTHWESTERN , Dallas , Texas , United States )
  • Ambardekar, Amrut  ( , Aurora , Colorado , United States )
    • Author Disclosures:
    Martha Grogan: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alnylam:Active (exists now) ; Advisor:NovoNordisk:Active (exists now) ; Advisor:AztraZeneca:Active (exists now) ; Consultant:Janssen:Active (exists now) ; Research Funding (PI or named investigator):Janssen:Past (completed) ; Research Funding (PI or named investigator):NovoNordisk:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Past (completed) ; Research Funding (PI or named investigator):Eidos:Active (exists now) | Michelle Kittleson: DO NOT have relevant financial relationships | Ajith Nair: DO have relevant financial relationships ; Speaker:Janssen:Active (exists now) ; Consultant:Abbott:Past (completed) ; Advisor:Gossamer Bio:Past (completed) ; Speaker:Impulse Dynamics:Past (completed) | Justin Grodin: DO have relevant financial relationships ; Researcher:Pfizer:Active (exists now) ; Consultant:Tenax Therapeutics:Active (exists now) ; Consultant:Lumanity:Past (completed) ; Consultant:Ultromics:Past (completed) ; Advisor:AstraZeneca:Active (exists now) ; Advisor:Eidos / BridgeBIo:Active (exists now) ; Advisor:Alexion:Past (completed) ; Advisor:Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Eidos / BridgeBio:Past (completed) | Amrut Ambardekar: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations

Monday, 11/18/2024 , 09:45AM - 11:00AM

Featured Science

More abstracts on this topic:
The prevalence of transthyretin cardiac amyloidosis in older Black and Hispanic individuals with heart failure: The Screening for Cardiac Amyloidosis with Nuclear imaging in Minority Populations Study

Ruberg Frederick, Blaner William, Deluca Albert, Johnson Lynne, Kinkhabwala Mona, Leb Jay, Mintz Akiva, Lavalley Michael, Einstein Andrew, Cohn Elizabeth, Kelly Jeffery, Teruya Sergio, Miller Edward, Maurer Mathew, Helmke Stephen, Fine Denise, Kurian Damian, Raiszadeh Farbod, Connors Lawreen, Prokaeva Tatiana, Pandey Shivda

Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy with Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy

Greenberg Barry, Coggins Matthew, Schwartz Jonathan, Rossano Joseph, Taylor Matthew, Colan Steven, Adler Eric, Ricks David, Yarabe Paul, Battiprolu Pavan, Shah Guarav, Patel Kinnari

More abstracts from these authors:
The Final Battle: Advanced Heart Failure and AF - HF Top 5 Take Aways

Ambardekar Amrut, Kittleson Michelle

Commentary: Gene Therapy for Cardiac Amyloid

Grogan Martha, Grodin Justin, Ambardekar Amrut

You have to be authorized to contact abstract author. Please, Login
Not Available